ReShape Lifesciences Inc. (NASDAQ:RSLS)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 1.45. At the close of trading, the stock’s price was $0.17, to imply an increase of 1.91% or $0.0 in intraday trading. The RSLS share’s 52-week high remains $1.29, putting it -658.82% down since that peak but still an impressive 17.65% since price per share fell to its 52-week low of $0.14. The company has a valuation of $5.02M, with an average of 0.28 million shares in intraday trading volume over the past 10 days and average of 6.28 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for ReShape Lifesciences Inc. (RSLS), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give RSLS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ReShape Lifesciences Inc. (NASDAQ:RSLS) trade information
After registering a 1.91% upside in the last session, ReShape Lifesciences Inc. (RSLS) has traded red over the past five days. The 5-day price performance for the stock is -4.68%, and -19.08% over 30 days. With these gigs, the year-to-date price performance is -31.56%. Short interest in ReShape Lifesciences Inc. (NASDAQ:RSLS) saw shorts transact 0.68 million shares and set a 0.27 days time to cover.
ReShape Lifesciences Inc. (RSLS) estimates and forecasts
The rating firms project that company’s revenue will grow 15.10% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is 1.97M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 2.51M.
RSLS Dividends
ReShape Lifesciences Inc. has its next earnings report out on 2024-Aug-14. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
ReShape Lifesciences Inc. (NASDAQ:RSLS)’s Major holders
ReShape Lifesciences Inc. insiders hold 8.91% of total outstanding shares, with institutional holders owning 1.41% of the shares at 1.55% float percentage. In total, 1.41% institutions holds shares in the company.
We also have Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the ReShape Lifesciences Inc. (RSLS) shares. Going by data provided on Jun 30, 2023 , Vanguard Extended Market Index Fund holds roughly 49.87 shares. This is just over 1.44% of the total shares, with a market valuation of $73813.0. Data from the same date shows that the other fund manager holds a little less at 1.73, or 0.05% of the shares, all valued at about 4193.0.
